Blog

Britain backs GSK’s gene therapy for ‘bubble boy’ syndrome – Reuters


Reuters

Britain backs GSK's gene therapy for 'bubble boy' syndrome
Reuters
Britain's National Institute for Health and Care Excellence (NICE) said in draft guidance published on Friday that Strimvelis gene therapy used against adenosine deaminase deficiency, or ADA-SCID, improves overall survival compared with standard stem
NHS to fund gene therapy for 'bubble babies' – The TelegraphTelegraph.co.uk


NICE approves gene therapy for rare 'bubble baby syndrome'NICE
NICE nod for GSK's 'bubble baby syndrome' gene therapyPharmaTimes
The Times
all 8 news articles »

2017-10-23 NEWS
About Michael Zand

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.